Literature DB >> 19887071

Identification of a sensitive anti-erythropoietin receptor monoclonal antibody allows detection of low levels of EpoR in cells.

Steve Elliott1, Leigh Busse, Ian McCaffery, John Rossi, Angus Sinclair, Chris Spahr, Susan Swift, C Glenn Begley.   

Abstract

Erythropoietin (Epo) binds and activates the Epo receptor (EpoR) on the surface of erythroid progenitor cells resulting in formation of erythrocytes. Recently, EpoR was reported to be expressed on non-erythroid cells suggesting a role for Epo outside of erythropoiesis. However those studies employed antibodies with questionable specificity and the significance of the observations are controversial. In order to accurately determine the expression of EpoR proteins in cells, we have generated a panel of novel anti-human EpoR monoclonal antibodies. One of these antibodies (A82) was particularly sensitive and it detected the EpoR protein on intact cells by flow cytometry and by western blot analysis with cell lysates. Both methods were optimized and using them, EpoR protein was detected by western immunoblotting with lysates from fewer than 200 EpoR positive control cells and the positive signals were proportional to EpoR protein expression level with a minimal signal in EpoR negative cells. The proteins detected by western blot analysis using A82 included full-length EpoR ( approximately 59kDa) as well as smaller EpoR fragments derived from the EPOR gene. These results indicate that A82 can be used to examine low level EpoR expression in cells by western and flow cytometry allowing an improved understanding of EpoR expression and metabolism. Copyright 2009 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19887071     DOI: 10.1016/j.jim.2009.10.006

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  25 in total

1.  Pyruvate protects the brain against ischemia-reperfusion injury by activating the erythropoietin signaling pathway.

Authors:  Myoung-Gwi Ryou; Ran Liu; Ming Ren; Jie Sun; Robert T Mallet; Shao-Hua Yang
Journal:  Stroke       Date:  2012-01-26       Impact factor: 7.914

Review 2.  Clinical pharmacokinetics and pharmacodynamics of erythropoiesis-stimulating agents.

Authors:  Sameer Doshi; Wojciech Krzyzanski; Susan Yue; Steven Elliott; Andrew Chow; Juan José Pérez-Ruixo
Journal:  Clin Pharmacokinet       Date:  2013-12       Impact factor: 6.447

Review 3.  Erythropoiesis, anemia and the bone marrow microenvironment.

Authors:  Carl R Walkley
Journal:  Int J Hematol       Date:  2011-01-12       Impact factor: 2.490

4.  Phospho-PTM proteomic discovery of novel EPO- modulated kinases and phosphatases, including PTPN18 as a positive regulator of EPOR/JAK2 Signaling.

Authors:  Matthew A Held; Emily Greenfest-Allen; Su Su; Christian J Stoeckert; Matthew P Stokes; Don M Wojchowski
Journal:  Cell Signal       Date:  2020-02-03       Impact factor: 4.315

5.  Quantitative comparison of erythropoietin receptor levels in the epithelial versus endothelial fractions of primary breast tumors.

Authors:  Chris P Miller; Nicole Urban; C Anthony Blau
Journal:  Anticancer Res       Date:  2011-04       Impact factor: 2.480

6.  Far-western blotting as a solution to the non-specificity of the anti-erythropoietin receptor antibody.

Authors:  Barbora Fecková; Patrícia Kimáková; Lenka Ilkovičová; Erika Szentpéteriová; Nataša Debeljak; Zuzana Solárová; Veronika Sačková; Martina Šemeláková; Mangesh Bhide; Peter Solár
Journal:  Oncol Lett       Date:  2016-06-24       Impact factor: 2.967

Review 7.  Targeting EPO and EPO receptor pathways in anemia and dysregulated erythropoiesis.

Authors:  Nicole Rainville; Edward Jachimowicz; Don M Wojchowski
Journal:  Expert Opin Ther Targets       Date:  2015-09-30       Impact factor: 6.902

8.  Erythropoietin increases macrophage-mediated T cell suppression.

Authors:  Michelle A Wood; Naomi Goldman; Kelley DePierri; John Somerville; James E Riggs
Journal:  Cell Immunol       Date:  2016-05-27       Impact factor: 4.868

9.  Widespread Expression of Erythropoietin Receptor in Brain and Its Induction by Injury.

Authors:  Christoph Ott; Henrik Martens; Imam Hassouna; Bárbara Oliveira; Christian Erck; Maria-Patapia Zafeiriou; Ulla-Kaisa Peteri; Dörte Hesse; Simone Gerhart; Bekir Altas; Tekla Kolbow; Herbert Stadler; Hiroshi Kawabe; Wolfram-Hubertus Zimmermann; Klaus-Armin Nave; Walter Schulz-Schaeffer; Olaf Jahn; Hannelore Ehrenreich
Journal:  Mol Med       Date:  2015-09-01       Impact factor: 6.354

Review 10.  Physiology and pharmacology of erythropoietin.

Authors:  Wolfgang Jelkmann
Journal:  Transfus Med Hemother       Date:  2013-07-19       Impact factor: 3.747

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.